{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T07:20:32Z","timestamp":1648970432433},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"18","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1097\/md.0000000000010683","type":"journal-article","created":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T16:43:36Z","timestamp":1525279416000},"page":"e0683","source":"Crossref","is-referenced-by-count":2,"title":["Optimal nonvitamin K antagonist oral anticoagulant therapy in a warfarin-sensitive patient after left atrial appendage closure"],"prefix":"10.1097","volume":"97","author":[{"given":"Long","family":"Shen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sha-Sha","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heng","family":"Ge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Qing","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Chun","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-65-20210309","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jcmg.2014.08.009","article-title":"The left atrial appendage: anatomy, function, and noninvasive evaluation","volume":"7","author":"Beigel","year":"2014","journal-title":"JACC Cardiovasc Imaging"},{"key":"R2-65-20210309","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1093\/europace\/euw295","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"18","author":"Kirchhof","year":"2016","journal-title":"Europace"},{"key":"R3-65-20210309","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1586\/14779072.2015.988612","article-title":"Antithrombotic therapy after left atrial appendage closure","volume":"13","author":"Schmidt","year":"2015","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"R4-65-20210309","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S0140-6736(09)61343-X","article-title":"Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial","volume":"374","author":"Holmes","year":"2009","journal-title":"Lancet"},{"key":"R5-65-20210309","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1161\/CIRCULATIONAHA.110.976449","article-title":"Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Registry","volume":"123","author":"Reddy","year":"2011","journal-title":"Circulation"},{"key":"R6-65-20210309","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2014.04.029","article-title":"Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial","volume":"64","author":"Holmes","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"R7-65-20210309","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1160\/TH13-06-0443","article-title":"Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis \u2013 Task Force on Anticoagulants in Heart Disease","volume":"110","author":"De Caterina","year":"2013","journal-title":"Thromb Haemost"},{"key":"R8-65-20210309","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.thromres.2017.08.012","article-title":"Study on a novel polymorphism in the VKORC1 promoter region using bioinformatic tools and warfarin dosing data","volume":"158","author":"Askari","year":"2017","journal-title":"Thromb Res"},{"key":"R9-65-20210309","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1001\/jama.2017.11469","article-title":"Effect of genotype-guided warfarin dosing on clinical events and anticoagulation control among patients undergoing hip or knee arthroplasty: The GIFT Randomized Clinical Trial","volume":"318","author":"Gage","year":"2017","journal-title":"JAMA"},{"key":"R10-65-20210309","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa0809329","article-title":"Estimation of the warfarin dose with clinical and pharmacogenetic data","volume":"360","author":"International Warfarin Pharmacogenetics Consortium","year":"2009","journal-title":"N Engl J Med"},{"key":"R11-65-20210309","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jcin.2009.05.005","article-title":"Percutaneous left atrial appendage occlusion for patients in atrial fibrillation suboptimal for warfarin therapy: 5-year results of the PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) Study","volume":"2","author":"Block","year":"2009","journal-title":"JACC Cardiovasc Interv"},{"key":"R12-65-20210309","doi-asserted-by":"crossref","first-page":"877","DOI":"10.4244\/EIJ-D-17-00042","article-title":"Safety and efficacy of early anticoagulation drug regimens after WATCHMAN left atrial appendage closure: three-month data from the EWOLUTION prospective, multicentre, monitored international WATCHMAN LAA closure registry","volume":"13","author":"Bergmann","year":"2017","journal-title":"EuroIntervention"},{"key":"R13-65-20210309","doi-asserted-by":"crossref","first-page":"j5058","DOI":"10.1136\/bmj.j5058","article-title":"Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis","volume":"359","author":"Lopez-Lopez","year":"2017","journal-title":"BMJ"},{"key":"R14-65-20210309","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ijcard.2016.09.129","article-title":"Efficacy and safety of novel anticoagulants versus vitamin K antagonists in patients with mild and moderate to severe renal insufficiency: focus on apixaban","volume":"225","author":"Pelliccia","year":"2016","journal-title":"Int J Cardiol"},{"key":"R15-65-20210309","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1093\/eurheartj\/ehr342","article-title":"Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment","volume":"32","author":"Fox","year":"2011","journal-title":"Eur Heart J"},{"key":"R16-65-20210309","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1253\/circj.CJ-12-0454","article-title":"Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation \u2013 the J-ROCKET AF study","volume":"76","author":"Hori","year":"2012","journal-title":"Circ J"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000010683","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T03:07:52Z","timestamp":1620961672000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201805040-00065"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":16,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000010683","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]}}}